Who are Methylene blue (1%)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Azilect, Auromid, Selegiline Hydrochloride, Humoryl, Nardil, Nardil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/methylene-blue-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Methylene blue (1%) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Methylene blue (1%) (Methylene blue (1%)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Redox agent; monoamine oxidase inhibitor. Area: Multiple (Toxicology, Psychiatry, Infectious Disease, Hematology).

marketed Redox agent; monoamine oxidase inhibitor Mitochondrial electron transport chain; monoamine oxidase; methemoglobin reductase Multiple (Toxicology, Psychiatry, Infectious Disease, Hematology) Small molecule Live · refreshed every 30 min

Target snapshot

Methylene blue (1%) (Methylene blue (1%)) — University Hospital, Strasbourg, France. Methylene blue acts as a redox agent and monoamine oxidase inhibitor, helping to restore cellular electron transport and reduce oxidative stress.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Methylene blue (1%) TARGET	Methylene blue (1%)	University Hospital, Strasbourg, France	marketed	Redox agent; monoamine oxidase inhibitor	Mitochondrial electron transport chain; monoamine oxidase; methemoglobin reductase
Azilect	RASAGILINE	Teva	marketed	Monoamine Oxidase Inhibitor	5-hydroxytryptamine receptor 6	2006-01-01
Auromid	MOCLOBEMIDE		marketed	Monoamine Oxidase Inhibitors	Amine oxidase [flavin-containing] A	1990-01-01
Selegiline Hydrochloride	SELEGILINE	Somerset	marketed	Monoamine Oxidase Inhibitor	Amine oxidase [flavin-containing] B	1989-01-01
Humoryl	TOLOXATONE		marketed	Monoamine Oxidase Inhibitors	Amine oxidase [flavin-containing] A	1984-01-01
Nardil	Phenelzine Sulfate	Pfizer	marketed	Monoamine Oxidase Inhibitor	Amine oxidase [flavin-containing] B	1961-01-01
Nardil	PHENELZINE	Pfizer	marketed	Monoamine Oxidase Inhibitor	Amine oxidase [flavin-containing] B	1961-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Redox agent; monoamine oxidase inhibitor class)

University Hospital, Strasbourg, France · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Methylene blue (1%) — Competitive Intelligence Brief. https://druglandscape.com/ci/methylene-blue-1. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing